Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. - Wikidata - awgldk - TriplyDB

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

http://www.wikidata.org/entity/Q37119137

about

FAK and paxillin, two potential targets in pancreatic cancer Pancreatic cancer Prioritizing therapeutic targets using patient-derived xenograft models Personalising pancreas cancer treatment: When tissue is the issue.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.mTOR inhibitors in urinary bladder cancer.Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.

P2860

Q26765360-BDAC0B34-2D32-4FB7-BF0F-6550360D7A7A Q27005724-14126889-8329-497C-A74E-2AF39B36C443 Q28083993-11859ACC-4AA6-48B6-B4FC-2047C8D26F83 Q33801384-700DB633-4E52-409B-AE05-EA0E4A9D1666 Q38666243-EAA3C334-9476-45A9-A61B-76A10434AAB8 Q38737064-19C6F1B0-1FFD-4BEF-AE95-FC4D4B6C6FC2 Q38992739-A6ED8F58-ACDD-4748-B66A-66A2DB2ADA2A Q40880050-CA3C2DF1-B350-4E0E-BB82-E1A595FF5103 Q42575030-BCEEED35-F585-4250-834C-3D1226D01644 Q52670846-5A659937-A638-494D-AE50-224E8FDCCC75

P2860

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

http://www.wikidata.org/entity/Q37119137

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Synergistic interactions betwe ...... tic cancer xenografts in mice.

@en

Synergistic interactions betwe ...... tic cancer xenografts in mice.

@nl

type

label

Synergistic interactions betwe ...... tic cancer xenografts in mice.

@en

Synergistic interactions betwe ...... tic cancer xenografts in mice.

@nl

prefLabel

Synergistic interactions betwe ...... tic cancer xenografts in mice.

@en

Synergistic interactions betwe ...... tic cancer xenografts in mice.

@nl

P1433

Q37119137-C3E59177-BD36-4461-BDFB-F0113D0475C6

P1476

Q37119137-07C32F67-84EF-454C-A4C0-43BE34E39B6C

P2093

Q37119137-1D51861A-AC10-440B-80B2-EC7687F9ED4B

Q37119137-2C544CF9-D41F-49A8-A1BA-C3FFA4C28182

Q37119137-37254D42-EB11-444B-9A1E-0453D667D911

Q37119137-426518CD-0AB1-4622-B843-032EC6839962

Q37119137-7E383306-6B66-410D-B463-DC35AF18B867

Q37119137-7EC5EFCB-9976-4A3F-B6E2-14A7A168E706

Q37119137-D9F3B0FC-6C93-4041-A1F9-0F0F76DB78EF

P2860

Q37119137-04119A4B-5319-4663-9E41-248B715F531B

Q37119137-0A27125B-CA3E-46CD-8DC9-A5381A8199FD

Q37119137-0A884515-D1D4-472F-868A-ACE116355329

Q37119137-0F955DA3-D65B-4E04-9934-7F40722A0A52

Q37119137-31557A52-567D-4431-8106-36B9C02C0717

Q37119137-3D1D4EE7-E9A4-43FB-9E61-189696F2DFDC

Q37119137-4306EC89-687A-4BA4-8CEA-D9B21D58508A

Q37119137-44EF28F4-1994-4BFB-B63F-76F8A41EB46F

Q37119137-4F21A0D0-5ECD-4315-8135-E7C7AB4E0AB1

Q37119137-51D25BEE-9234-423A-8DAC-D59AA695F1E7

P2888

Q37119137-7AF80E14-0215-40E4-AEA8-4146D036B546

P304

Q37119137-1D6FAFBE-3D68-43BF-B499-B33436D8DDA3

P31

Q37119137-6F352F33-E14C-475F-BA55-40DE7F39CCD0

P356

Q37119137-D30DD91D-27AB-45C6-9B21-027937F87BDF

P433

Q37119137-1CEA55EE-CF21-4046-9AA1-97491A809B2E

P478

Q37119137-F500D868-B39F-41D6-B329-1D40BD71F867

P577

Q37119137-F8C8FCBD-CBF2-46FA-9DFD-25FC7F768C0D

P698

Q37119137-0BE50043-53AE-4A2D-BECB-43ED5A153610

P921

Q37119137-75DBB77F-A1A9-4B17-B39D-E9AE3D913880

P932

Q37119137-FD12ADF2-49DA-4729-914F-DDB29B8657F4

P356

S00280-013-2117-X

P1433

Cancer Chemotherapy and Pharmacology

P1476

Synergistic interactions betwe ...... tic cancer xenografts in mice.

@en

P2093

Bonnie H Hylander

http://www.w3.org/2001/XMLSchema#string

Dipti K Pawaskar

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Repasky

http://www.w3.org/2001/XMLSchema#string

Gerald J Fetterly

http://www.w3.org/2001/XMLSchema#string

Robert M Straubinger

http://www.w3.org/2001/XMLSchema#string

Wen W Ma

http://www.w3.org/2001/XMLSchema#string

William J Jusko

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice

Sorafenib: a review of its use in advanced hepatocellular carcinoma

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Pancreatic cancer.

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

P2888

s00280-013-2117-x

P304

1231-1240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2117-X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23455452

http://www.w3.org/2001/XMLSchema#string

P921

P932

3752659

http://www.w3.org/2001/XMLSchema#string